Loading…
📊 Analyst reports All ratings →
09-17Buy · ₩280,000Daishin Securities: Omlyclo's Potential Confirmed in Europe08-03Buy · ₩247,823SK Securities: 2Q26 Re: Profitability improvement in full swing07-28Buy · ₩260,000iM Securities: Now in a reliable position07-28Buy · ₩280,000Yuanta Securities: 2Q26 Review: Continued new product effects07-28Buy · ₩290,000Sangsangin Securities: New product expansion continues into 2H
📑 Recent filings Filings Radar →
09.23★★★🟢 Zymfentra US Phase 3 clinical trial approval (rheumatoid arthritis)09.23★★ Large Shareholding Report (General)09.21★★★🟢 Darzalex biosimilar EU Phase 3 clinical trial approval09.16★★🟢 Cancellation of treasury shares for stock price stabilization and shareholder value enhancement09.07★★★🟢 Keytruda biosimilar US Phase 3 clinical trial amendment approval09.07★★★🟢 Darzalex biosimilar Korea Phase 3 clinical trial amendment approval
RSI 14
ExploreAll top movers →
Today's top 5 gainers
1WisePlanet Company+285.8%2TN Entertainment+30.0%3Phionx+30.0%4HT Robotics+29.9%5Woorinet+29.9%
More on KOSPI News
🔥 Today's top moversForeign flowsDividendsIPO calendarWeekly picksFilings